ACETO Subsidiary, Rising Pharmaceuticals, to Launch Dutasteride Softgel Capsules
November 24 2015 - 9:00AM
ACETO Corporation (NASDAQ:ACET), with offices and operations in 10
countries and engaged in the marketing, sale and distribution of
Human Health products, Pharmaceutical Ingredients and Performance
Chemicals, today announced that Rising Pharmaceuticals, Inc., its
finished dosage form generics subsidiary, is launching
Dutasteride Softgel Capsules 0.5mg, an
FDA-approved generic version of GlaxoSmithKline LLC's Avodart.
According to IMS Health data, U.S. market sales for Dutasteride
Softgel Capsules, which is used for the treatment of symptomatic
benign prostatic hyperplasia (BPH) in men with an enlarged
prostate, were approximately $452 million for the twelve months
ended September 30, 2015. This product is one of the three soft gel
products acquired from Par Pharmaceuticals in September 2014.
ABOUT ACETO
ACETO Corporation, incorporated in 1947 and with offices and
business operations in 10 countries, is engaged in the marketing,
sale and distribution of Human Health products (finished dosage
form generics and nutraceutical products), Pharmaceutical
Ingredients (pharmaceutical intermediates and active pharmaceutical
ingredients) and Performance Chemicals (specialty chemicals and
agricultural protection products). ACETO distributes over 1,100
chemical compounds used principally as finished products or raw
materials in the pharmaceutical, nutraceutical, agricultural,
coatings and industrial chemical industries. ACETO's global
operations, including a staff of 25 in China and 12 in India, are
distinctive in the industry and enable its worldwide sourcing and
regulatory capabilities.
FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements as that
term is defined in the federal securities laws. The events
described in forward-looking statements contained in this news
release may not occur. Generally, these statements relate to our
business plans or strategies, projected or anticipated benefits or
other consequences of ACETO's plans or strategies, financing plans,
projected or anticipated benefits from acquisitions that ACETO may
make, or a projection involving anticipated revenues, earnings or
other aspects of ACETO's operating results or financial position,
and the outcome of any contingencies. Any such forward-looking
statements are based on current expectations, estimates and
projections of management. ACETO intends for these forward-looking
statements to be covered by the safe-harbor provisions for
forward-looking statements. Words such as "may," "will," "expect,"
"believe," "anticipate," "project," "plan," "intend," "estimate,"
and "continue," and their opposites and similar expressions are
intended to identify forward-looking statements. The
forward-looking statements contained in this press release include,
but are not limited to, statements regarding the Company's
strategic initiatives including selling finished dosage form
generic drugs, and statements regarding the prospects for long-term
growth. ACETO cautions you that these statements are not guarantees
of future performance or events and are subject to a number of
uncertainties, risks and other influences, many of which are beyond
ACETO's control, which may influence the accuracy of the statements
and the projections upon which the statements are based. Factors
that could cause actual results to differ materially from those set
forth or implied by any forward-looking statement include, but are
not limited to, risks and uncertainties discussed in ACETO's
reports filed with the Securities and Exchange Commission,
including, but not limited to, ACETO's Annual Report or Form 10-K
for the fiscal year ended June 30, 2015 and other filings. Copies
of these filings are available at www.sec.gov.
Any one or more of these uncertainties, risks and other
influences could materially affect ACETO's results of operations
and whether forward-looking statements made by ACETO ultimately
prove to be accurate. In addition, periodic high-margin product
sales may have a positive material financial impact in a given
quarter that may be non-recurring in future quarters, thereby
rendering one quarter's performance not useful as a predictor of
future quarters' results. ACETO's actual results, performance and
achievements could differ materially from those expressed or
implied in these forward-looking statements. ACETO undertakes no
obligation to publicly update or revise any forward-looking
statements, whether from new information, future events or
otherwise.
CONTACT: Investor Relations Contact:
LHA
Jody Burfening
jburfening@lhai.com
(212) 838-3777